NCT00637806

Treatment of Cancer-associated Anorexia Using Megestrol Acetate Concentrated Suspension

A Randomized, Double-blind, Placebo-controlled Study of Megestrol Acetate Concentrated Suspension for the Treatment of Cancer-associated Anorexia in Subjects With Cancer of Multiple Types

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 4 (actual)
• Sponsor: Par Pharmaceutical, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To compare the effect of megestrol acetate concentrated suspension and placebo on caloric intake in patients with cancer-associated anorexia.

Conditions

• Anorexia
• Cachexia
• Weight Loss

Interventions

Type	Name	Description
DRUG	Megestrol acetate concentrated suspension 110 mg/mL	Megestrol acetate concentrated suspension 110 mg/mL given as an oral dose of 550 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
DRUG	Megestrol acetate concentrated suspension 60 mg/mL	Megestrol acetate concentrated suspension 60 mg/mL given as an oral dose of 300 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
DRUG	Placebo	Placebo oral suspension, 5 mL once daily

Timeline

• Start date: 2006-06-01
• Primary completion: 2006-09-01
• Completion: 2006-09-01
• First posted: 2008-03-18
• Last updated: 2016-05-02
• Results posted: 2016-05-02

Locations

4 sites across 1 country: United States